Editorial Advisory Board member Dr. Socinski discusses the key clinical insights brought to light by the POINTBREAK trial, presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
An expert reviews the new maintenance, second- and third-line therapies for colorectal cancer treatment presented at the 2013 Gastrointestinal Cancers Symposium.
In this article, Advisory Board member Neal Shore, MD, FACS, discusses barriers to clinicians recommending active surveillance for men with low-risk prostate cancer.
Advisory Board Member Dr. Farma reviews the current recommendations for using sentinel lymph node biopsy in patients with melanoma.
This patient, who had an increasing PSA level, was found to have abnormal PCA3 urine test results.
Advisory Board member Neal D. Shore, MD, FACS relates how vital it is that urologists recognize the changing demands of the field.
The guidelines include several departures from past recommendations on the diagnosis, workup, and evaluation of microhematuria.
Advisory Board member Tara Morrison, MD, a renowned expert in the treatment of brain cancer, reviews a novel brain tumor therapy.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|